{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:48:11Z","timestamp":1790200091958,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.hoc.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T19:34:36Z","timestamp":1510947276000},"page":"75-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Treatment of Kaposi Sarcoma Herpesvirus\u2013Associated Multicentric Castleman Disease"],"prefix":"10.1016","volume":"32","author":[{"given":"Kathryn","family":"Lurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2017.09.007_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002030-199601000-00009","article-title":"Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients","volume":"10","author":"Oksenhendler","year":"1996","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.007_bib2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.007_bib3","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice","volume":"86","author":"Brandt","year":"1990","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.007_bib5","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069.h8002069_2069_2073","article-title":"High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients","volume":"96","author":"Oksenhendler","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.007_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdn697","article-title":"The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease","volume":"20","author":"Powles","year":"2009","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2017.09.007_bib7","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","article-title":"Clinical features and outcome in HIV-associated multicentric Castleman's disease","volume":"29","author":"Bower","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.007_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2007-03-080648","article-title":"Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T\u00a0cells","volume":"111","author":"Guihot","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.007_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nm0896-925","article-title":"KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma","volume":"2","author":"Gao","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2017.09.007_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-9378-6-22","article-title":"Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa","volume":"6","author":"Maskew","year":"2011","journal-title":"Infect Agent Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.007_bib12","doi-asserted-by":"crossref","first-page":"e21286","DOI":"10.1371\/journal.pone.0021286","article-title":"Human herpesvirus 8 seropositivity among sexually active adults in Uganda","volume":"6","author":"Shebl","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2017.09.007_bib13","doi-asserted-by":"crossref","first-page":"20122","DOI":"10.7448\/IAS.18.1.20122","article-title":"Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi","volume":"18","author":"Gopal","year":"2015","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"24","key":"10.1016\/j.hoc.2017.09.007_bib14","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2017.09.007_bib15","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1182\/blood-2012-02-387092","article-title":"Meeting the challenge of hematologic malignancies in sub-Saharan Africa","volume":"119","author":"Gopal","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.007_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic Kaposi sarcoma Herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS)","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.007_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/654798","article-title":"An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease","volume":"51","author":"Uldrick","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.hoc.2017.09.007_bib18","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1073\/pnas.140129797","article-title":"Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis","volume":"97","author":"Coscoy","year":"2000","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1172\/JCI200524041","article-title":"Regulation of CD1d expression and function by a herpesvirus infection","volume":"115","author":"Sanchez","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.hoc.2017.09.007_bib20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2016-06-719716","article-title":"iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease","volume":"129","author":"Sbihi","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2017.09.007_bib21","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2013-01-480665","article-title":"Innate immune control of EBV-infected B cells by invariant natural killer T\u00a0cells","volume":"122","author":"Chung","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1172\/JCI44185","article-title":"KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation","volume":"121","author":"Hassman","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.hoc.2017.09.007_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0002-9440(10)64940-1","article-title":"Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease","volume":"156","author":"Parravicini","year":"2000","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib24","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/JVI.73.5.4181-4187.1999","article-title":"Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease","volume":"73","author":"Staskus","year":"1999","journal-title":"J\u00a0Virol"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/viro.2000.0196","article-title":"Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease","volume":"269","author":"Katano","year":"2000","journal-title":"Virology"},{"issue":"26","key":"10.1016\/j.hoc.2017.09.007_bib26","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2017.09.007_bib27","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2008-12-197053","article-title":"Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease","volume":"113","author":"Bower","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2017.09.007_bib28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0198-8859(99)00083-X","article-title":"KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways","volume":"60","author":"Osborne","year":"1999","journal-title":"Hum Immunol"},{"issue":"5293","key":"10.1016\/j.hoc.2017.09.007_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1126\/science.274.5293.1739","article-title":"Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV","volume":"274","author":"Moore","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/152581600319351","article-title":"Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6","volume":"9","author":"Aoki","year":"2000","journal-title":"J\u00a0Hematother Stem Cell Res"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.007_bib31","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V97.8.2526","article-title":"Serum viral interleukin-6 in AIDS-related multicentric Castleman disease","volume":"97","author":"Aoki","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.007_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/JVI.01192-15","article-title":"Induction of Kaposi's Sarcoma-associated Herpesvirus-encoded viral interleukin-6 by X-box binding protein 1","volume":"90","author":"Hu","year":"2015","journal-title":"J\u00a0Virol"},{"issue":"22","key":"10.1016\/j.hoc.2017.09.007_bib33","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2011-09-377705","article-title":"HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice","volume":"119","author":"Suthaus","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2017.09.007_bib34","doi-asserted-by":"crossref","first-page":"e1004581","DOI":"10.1371\/journal.ppat.1004581","article-title":"Systemic expression of Kaposi sarcoma herpesvirus (KSHV) Vflip in endothelial cells leads to a profound proinflammatory phenotype and myeloid lineage remodeling in\u00a0vivo","volume":"11","author":"Ballon","year":"2015","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.007_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jiv204","article-title":"18F-fluorodeoxyglucose positron emission tomography in Kaposi Sarcoma Herpesvirus-associated multicentric Castleman Disease: correlation with activity, severity, inflammatory and virologic parameters","volume":"212","author":"Polizzotto","year":"2015","journal-title":"J\u00a0Infect Dis"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.007_bib36","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1080\/10428190410001693533","article-title":"Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels","volume":"45","author":"Newsom-Davis","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1086\/375224","article-title":"Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients","volume":"37","author":"Fardet","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.007_bib38","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma","volume":"95","author":"Dupin","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2559.2008.03144.x","article-title":"Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD)","volume":"53","author":"Chadburn","year":"2008","journal-title":"Histopathology"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.007_bib40","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2002-02-0487","article-title":"KSHV- and EBV-associated germinotropic lymphoproliferative disorder","volume":"100","author":"Du","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.semdp.2016.05.006","article-title":"Multicentric Castleman disease: where are we now?","volume":"33","author":"Wang","year":"2016","journal-title":"Semin Diagn Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib42","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1309\/AJCPKGF7U8AWQBVG","article-title":"Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"139","author":"Venkataraman","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2017.09.007_bib43","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease","volume":"99","author":"Oksenhendler","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2017.09.007_bib44","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood-2011-08-376012","article-title":"Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease","volume":"119","author":"Gerard","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2017.09.007_bib45","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2010-07-290213","article-title":"How I treat HIV-associated multicentric Castleman disease","volume":"116","author":"Bower","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2017.09.007_bib46","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1086\/342696","article-title":"Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy","volume":"35","author":"Aaron","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.007_bib47","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.hoc.2017.09.007_bib48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.hoc.2017.09.007_bib49","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial","volume":"25","author":"Gerard","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2017.09.007_bib50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/cid\/cis1009","article-title":"Human herpesvirus 8-related Castleman disease in the absence of HIV infection","volume":"56","author":"Dossier","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.hoc.2017.09.007_bib51","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","article-title":"Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2017.09.007_bib52","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-07-0939","article-title":"Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells","volume":"67","author":"Davis","year":"2007","journal-title":"Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2017.09.007_bib53","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2017.09.007_bib54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ajh.20418","article-title":"Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease","volume":"79","author":"Neuville","year":"2005","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.hoc.2017.09.007_bib55","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/QAD.0b013e3282f7371f","article-title":"Rituximab failure in fulminant multicentric HIV\/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases","volume":"22","author":"Buchler","year":"2008","journal-title":"AIDS"},{"issue":"15","key":"10.1016\/j.hoc.2017.09.007_bib56","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2016-10-747477","article-title":"Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients","volume":"129","author":"Pria","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2017.09.007_bib57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2011-02-335620","article-title":"Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease","volume":"118","author":"Stebbing","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2017.09.007_bib58","first-page":"4653","article-title":"Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence","volume":"9","author":"Trikha","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2017.09.007_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2017.09.007_bib60","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.hoc.2017.09.007_bib61","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi's Sarcoma in people with and without HIV infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2017.09.007_bib62","doi-asserted-by":"crossref","first-page":"50342","DOI":"10.18632\/oncotarget.17960","article-title":"Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide","volume":"8","author":"Davis","year":"2017","journal-title":"Oncotarget"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858817301478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:06:18Z","timestamp":1760184378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858817301478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0889858817301478"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Kaposi Sarcoma Herpesvirus\u2013Associated Multicentric Castleman Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}